Naphazoline

Naphazoline (Naphthazoline) is a potent α-adrenergic receptor agonist. Naphazoline reduces vascular hyperpermeability and promotes vasoconstriction. Naphazoline reduces the levels of inflammatory factors (TNF-α, IL-1β and IL-6), cytokines (IFN-γ and IL-4), IgE, GMCSF, and NGF. Naphazoline can be used for non-bacterial conjunctivitis research[1][2].

Product Specifications

CAS Number

[835-31-4]

Product Name Alternative

Naphthazoline

UNSPSC

12352005

Hazard Statement

H315, H319, H320

Target

Adrenergic Receptor; Interleukin Related; TNF Receptor; VEGFR

Type

Reference compound

Related Pathways

Apoptosis; GPCR/G Protein; Immunology/Inflammation; Neuronal Signaling; Protein Tyrosine Kinase/RTK

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Cardiovascular Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/naphazoline.html

Purity

99.74

Solubility

DMSO : 62.5 mg/mL (ultrasonic)

Smiles

C1(CC2=C3C=CC=CC3=CC=C2)=NCCN1

Molecular Formula

C14H14N2

Molecular Weight

210.27

Precautions

H315, H319, H320

References & Citations

[1]Quan L, et, al. Treatment with olopatadine and naphazoline hydrochloride reduces allergic conjunctivitis in mice through alterations in inflammation, NGF and VEGF. Mol Med Rep. 2016 Apr;13 (4) :3319-25.|[2]Yamaguchi I, et, al. Central and peripheral adrenergic mechanisms regulating gastric secretion in the rat. J Pharmacol Exp Ther. 1977 Oct;203 (1) :125-31.